Antinol® EAB-277® – The Executive Summary

Antinol® Rapid is a potent synergistic blend of 2 marine lipid extracts chosen for their unique enhancement formula called EAB-277®.

EAB-277® is the key active ingredient of this advanced formula formulated to promote optimal benefits through its synergistic efficacy contains > 90 free fatty acids full spectrum of Omega 3 including ETA, EPA, DHA as well as other key Polyunsaturated fatty acids (PUFAs) and antioxidants.

The two marine lipids used in Antinol® Rapid are proprietary and exclusively produced. The exact combination of 30mg lipid fractions from Perna canaliculus (New Zealand green lipped mussel) and 20mg high phospholipid krill oil is the result of years of research combining and isolating lipid groups and essential fatty acids to find the optimal nutrient synergy.

EAB-277®’s proprietary high phospholipid krill oil is high in polar lipid enrichment which enhances bioactivity “Potency” of this marine oil blend formula as a result of proven efficacy.

The Antinol® Rapid EAB-277® blend has been proven via laboratory tests to be more effective than either of the individual lipids alone in inhibiting inflammation markers such as nitric oxide, TNFα, and IL-6.

 

. . . VIEW

. . . VIEW

The Summary of the clinical researches and publications on www.antinol.com/studies

There has been several clinical trials looking at efficacy in canine osteoarthritis of the hip, stifle, and shoulder joints, as well as its effect in the post-surgical treatment of animals undergoing joint surgery.

The Executive Summary also includes the section about Safety in Canine, Human OA studies, Research in laboratory animals, and In vitro research.

 

. . . VIEW

. . . VIEW

Bone fracture is common in stray cats. It can cause severe pain and requires surgical treatment.

Use of non-steroidal anti-inflammatory drugs (NSAIDs) or opioid drugs is common for control of pain from bone fracture. However, adverse effects are frequently reported for NSAIDs and opioid use.

Objective of this study is to evaluate anti-inflammatory and pain-relieving effects and safety of PCSO-524® (Antinol®) for bone surgery in pregnant cats.

 

. . . VIEW

. . . VIEW

A 3 years old domestic short hair cat had shown behavioral disorder after castration 4 months ago.

The clinical signs were consistent with obsessive-compulsive disorders (OCD).

Pathological examination found edema of epidermis andinfiltration of mature mast cells in hair follicle. Treatment with PCSO-524® (Antinol)® for 180 days had shown that the misbehavior was improved due to decreased pain and skin inflammation. Healthier coat and skin appearance was noticed after 30 consecutive days of PCSO-524® (Antinol®) intake. Pathological follow-up showed less inflammation of epidermis and decreased mast cells infiltration.

It was shown that PCSO-524® (Antinol®) could reduce pain and inflammation that caused anxiety and consequently OCD in cats. Additional effects included antihistamine, antiallergy, and skin neurishing.

 

. . . VIEW

 

 

. . . VIEW

Male Yorkshire terrier dog aged 7 years weight 2.5 kg suffered from lameness of left Hind limb.

Examination found medial patellar luxation of grade 3 and chronic cranial cruciate ligament rupture.

PCSO-524® (Antinol®) 100 mg per day, double size of recommended dose for dogs weighed less than 20kg, was prescribed.

Examination of lameness score and pain on palpation showed improvement after PCSO-524® (Antinol®) treatment. Radiographic images taken before and after 45 days treatment with PCSO-524® (Antinol®) did not find progress of the lesion.

Hematological and biochemistry parameters after 45 days treatment with PCSO-524® (Antinol®) indicated that the medication was safe to use.

 

. . . VIEW

. . . VIEW

A randomized complete blocked design was assigned to 40 healthy Beagle dogs aged between 1 to 3 years old. All dogs were separated into 4 groups, each of which had 5 males and 5 females.

Adaptation and test periods were of 2 and 8 weeks duration, respectively.

Four dietary treatments were composed of basal diet plus 20 empty capsules as placebo (negative control), basal diet plus 2 (the recommended dose), 6 (3 times the recommended dose) and 20 capsules (10 times the recommended dose) of n-3 PUFAs (PCSO-524®: Antinol®).

. . . VIEW

. . . VIEW

Chronic pain is commonly caused by degenerative disease, which is under diagnosed in cats.

PCSO-524 is an extract of Perna canaliculus, a known source of Omega-3 polyunsaturated fatty acids (PUFAs) with anti-inflammatory properties. Lipids extracted from the New Zealand green-lipped mussel (NZGLM) contain a complex mixture of mainly phospholipids (PL, 57-79%), triglycerides (TG, 10-25%), free fatty acids (FFA, 7-12%) and sterols (ST, 12-18%)

PCSO-524 is a source of omega-3 polyunsaturated fatty acids with anti-inflammatory properties commonly used to treat osteoarthritis in human beings and dogs.

The purpose of this study was to study the effects of PCSO-524 extract on vital signs, completed blood count, and blood chemistry in clinically-healthy normal cats.

 

 

. . . VIEW

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted

 

Discover More Studies
Click to see the library